TIFFANY HILBUN: Open Payments
NPI 1013396837 · LAUREL, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$919 in 47 payments from 15 companies in 2025. Trend: 2023 $1,912 · 2024 $1,508 · 2025 $919
Food & beverage: $919
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $182 |
| Otsuka America Pharmaceutical, Inc. | 5 | $124 |
| Octapharma USA, Inc. | 5 | $111 |
| ACADIA Pharmaceuticals Inc | 5 | $110 |
| PFIZER INC. | 5 | $85 |
| SK Life Science, Inc. | 2 | $61 |
| Novartis Pharmaceuticals Corporation | 2 | $45 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Eisai Inc. | 2 | $36 |
| Inspire Medical Systems, Inc. | 1 | $28 |
Products named: REXULTI, QULIPTA, PANZYGA, NUPLAZID, NURTEC ODT, UBRELVY, KESIMPTA, Symbravo.
Industry payments across MS — which companies pay providers there.
